Standout Papers
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (2012)
- Cancer cell killing via ROS: To increase or decrease, that is the question (2008)
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial (2016)
Immediate Impact
7 by Nobel laureates 13 from Science/Nature 64 standout
Citing Papers
Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Accurate proteome-wide missense variant effect prediction with AlphaMissense
2023 StandoutScienceNobel
Works of Jing Yi being referenced
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
Endothelial SUR‐8 acts in an ERK‐independent pathway during atrioventricular cushion development
2010
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Jing Yi | 3141 | 1187 | 1697 | 34 | 5.0k | |
| Jan B. Vermorken | 3032 | 1292 | 2106 | 43 | 5.4k | |
| J Carmichael | 4765 | 2240 | 1431 | 76 | 7.2k | |
| Gerrit Los | 1653 | 1797 | 1013 | 94 | 4.1k | |
| Madappa N. Kundranda | 2372 | 2528 | 1382 | 63 | 5.8k | |
| Deborah A. Altomare | 1650 | 3988 | 1266 | 68 | 6.3k | |
| Helen K. Angell | 3924 | 2061 | 1843 | 37 | 6.3k | |
| A. Hilary Calvert | 2996 | 2229 | 1064 | 74 | 5.8k | |
| Yiping Zhang | 3453 | 3055 | 1299 | 179 | 6.1k | |
| Judith Michels | 2008 | 2453 | 548 | 54 | 4.5k | |
| Goli Samimi | 2281 | 2556 | 522 | 64 | 5.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...